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Abstract
Background: Excessive production of nitric oxide (NO) by inducible nitric oxide synthase (iNOS) in reactive
microglia is a major contributor to initiation/exacerbation of inflammatory and degenerative neurological diseases.
Previous studies have indicated that activation of protein kinase C (PKC) can lead to iNOS induction. Because of the
existence of various PKC isoforms and the ambiguous specificity of PKC inhibitors, it is unclear whether all PKC
isoforms or a specific subset are involved in the expression of iNOS by reactive microglia. In this study, we
employed molecular approaches to characterize the role of each specific PKC isoform in the regulation of iNOS
expression in murine microglia.
Methods: Induction of iNOS in response to bacterial endotoxin lipopolysaccharide (LPS) was measured in BV-2
murine microglia treated with class-specific PKC inhibitors, or transfected with siRNA to silence specific PKC
isoforms. iNOS expression and MAPK phosphorylation were evaluated by western blot. The role of NF-Bi n
activated microglia was examined by determining NF-B transcriptional response element- (TRE-) driven, promoter-
mediated luciferase activity.
Results: Murine microglia expressed high levels of nPKCs, and expressed relatively low levels of cPKCs and aPKCs.
All PKC inhibitors attenuated induction of iNOS in LPS-activated microglia. Knockdown of PKC δ and PKC b
attenuated ERK1/2 and p38 phosphorylation, respectively, and blocked NF-B activation that leads to the
expression of iNOS in reactive microglia.
Conclusions: Our results identify PKC δ and b as the major PKC isoforms regulating iNOS expression in reactive
microglia. The signaling pathways mediated by PKC involve phosphorylation of distinct MAPKs and activation of
NF-B. These results may help in the design of novel and selective PKC inhibitors for the treatment of many
inflammatory and neurological diseases in which production of NO plays a pathogenic role.
Background
Microglia are distributed throughout the central nervous
system (CNS) as resting immunocompetent cells derived
from a monocyte/macrophage lineage [1,2]. When acti-
vated, microglia protect neurons by clearing toxic cell
debris and pathogens, and acting as antigen presenting
cells to induce innate immune responses [3]. However,
excessive activation of microglia can also release a vari-
ety of toxic factors including reactive oxygen species
(ROS), reactive nitrogen species (RNS) and proinflam-
matory cytokines, which cause toxicity to the
neighboring cells such as neurons and oligodendrocytes
(OLs). A pathogenic role for nitric oxide has been impli-
cated in many inflammatory and neurodegenerative dis-
eases, including multiple sclerosis, stroke and traumatic
brain injury [4-7]. Understanding the potential mechan-
isms that turn beneficial inflammatory responses into
detrimental action is crucial for identifying therapeutic
targets to intervene in self-sustained inflammatory
cycles.
Nitric oxide (NO), generated from L-arginine by nitric
oxide synthase (NOS), has been shown to be both a sig-
naling and an effector molecule in diverse biological sys-
tems [8-10]. Among the three isoforms of NOS
identified, neuronal NOS (nNOS) and endothelial NOS
(eNOS) are Ca
2+ dependent [8-13], and inducible NOS
(iNOS) functions in a Ca
2+-independent manner [10,13].
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microglia in response to endotoxin or to proinflamma-
tory cytokines, such as TNFa, IL-1b or IFNg [14]. Using
pharmacological inhibitors and molecular approaches,
studies have shown that NO can react with superoxide
to form peroxynitrite in reactive microglia causing toxi-
city to neurons and OLs [15,16]. Although it is known
that activation of various transcription factors - such as
STAT, NF-B, AP-1, and C/ERP - can contribute to the
production of NO [17-20], the signaling pathways regu-
lating expression of iNOS and production of NO in the
CNS are still not well understood.
Protein kinase C (PKC) is a family of serine/threonine
kinases that regulate cellular responses elicited by hor-
mones, neurotransmitters and growth factors [21].
Based on differences in sequence homology between
these isozymes and their requirements for cofactors, the
PKC family is divided into conventional PKCs (cPKC: a,
b and g), novel PKCs (nPKC: δ, ε, h and θ)a n da t y p i c a l
PKCs (aPKCs: ζ and l/ι) [22,23]. PKC isoforms are
widely expressed in many cell types, including micro-
glia/macrophages [24], and studies have shown that
PKC activation is an important mediator of microglial
activation [25,26]. PKC inhibitors reduce NO synthesis
from IFN-g-treated microglia and PKC δ is able to regu-
late NF-B activation and iNOS expression in mouse
peritoneal macrophages [27]. Because of the existence of
various PKC isoforms and the ambiguity of action of
P K Ci n h i b i t o r s ,t h er o l eo fs p e c i f i cP K Ci s o f o r m s
involved in the inflammatory response in microglia has
not been elucidated. In this study we used murine
microglial cell line BV-2 cells to examine the signaling
pathways by which PKC activation leads to iNOS induc-
tion in LPS-activated microglia. Our results indicate that
all PKC isoforms are expressed in BV-2 cells with a par-
ticularly high expression ofn P K C .A l t h o u g hs e v e r a l
PKC isoforms can mediate lipopolysaccharide- (LPS-)
stimulated increases in iNOS expression, PKC δ and b
are likely the major PKC isoforms responsible for PKC
function in reactive microglia. Furthermore, we found
that distinct mitogen activated protein kinases (MAPKs)
are activated in response to specific PKC isoforms and
result in iNOS induction. Elucidation of the signaling
pathways mediated by the different PKC isoforms in
iNOS expression in reactive microglia will facilitate the
development of isoform-specific PKC inhibitors with the
potential to avoid the side effects of pan-PKC inhibitors.
Methods
Materials
Fetal bovine serum (FBS) and Dulbecco’sm o d i f i e d
Eagle’s medium (DMEM) were purchased from Invitro-
gen (Carlsbad, CA). The BV-2 cell line was a generous
gift from Dr. Feng-Qiao Li, Cognosci Inc., NC. Bacterial
LPS (Escherichia Coli O111:B4) was obtained from
S i g m a( S t .L o u i s ,M O ) .2 ’,7’-dichlorohydrofluorescein
diacetate (DCF) was purchased from Molecular Probes,
Inc. (Eugene, OR). Antibodies against phosphorylated
and total p38, extracellular signal regulated kinase 1/2
(ERK1/2) and c-Jun N-terminal kinase (JNK) were pur-
chased from Cell Signaling Technology (Danvers, MA).
Anti-iNOS antibody was purchased from BD biosciences
(San Diego, CA). PKC siRNAs were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Bisindolyl-
maleimide-1 (Bis-1), Rottlerin, GO6976, SB203580,
SP600125 and U0126 were purchased from Calbiochem
(Gibbstown, NJ). Transfection reagents were from
Roche (Basel, Switzerland) and Luciferase assay kit was
from Promega (Madison, WI).
Cell culture
Immortalized murine microglial cells (BV-2) were cul-
tured in 100 mm dishes in DMEM containing 5% FBS,
1% penicillin/streptomycin at 37°C in an incubator with
a humidified atmosphere of 95% air and 5% CO2.
Quantitative real-time PCR and reverse transcriptase PCR
analysis
Total RNA was isolated from cultured BV-2 cells using
RNeasy Mini Kit (Qiagen, Valencia, CA) and cDNA
synthesis from total RNA was performed using a Rever-
iAid First Strand cDNA synthesis kit (Fermentas, Glen
Burnie, MD) using 1 µg total RNA and 1 μl oligo (dT)18
following the manufacturer’s instructions. Quantitative
real time PCR was conducted with cDNA as a template
in a 7500 Real time PCR System using SYBR Green
PCR master mix (Applied Biosystems, Foster city, CA).
The primers for target genes are shown in table 1. All
samples were run in triplicate for PCR amplification.
Relative values for mRNA expression were determined
from their optimized threshold cycle (CT)n o r m a l i z e d
against the CT value of an internal control gene,
GAPDH, by using the comparative CT method (User
Bulletin 7500, Applied Biosystems). To test for downre-
gulation of PKC isoforms by specific PKC siRNA, total
mRNA isolated from PKC siRNA or RISC-free siRNA-
transfected BV-2 cells was used to synthesize cDNA as
described above. One microliter of each cDNA, synthe-
sized in a reverse transcriptase reaction, was used for
PCR amplification in the presence of 1 U Taq DNA
polymerase in Tag buffer, 0.2 mM each of dNTPs, and
1 μM of each primer. Each sample was amplified for dif-
ferent cycles according to the expression level of each
gene in the cells. PKC a, b and θ were amplified for 32
cycles, PKC ε and h were amplified for 28 cycles, and
PKC δ was amplified for 26 cycles. The PCR amplifica-
tion reaction used a three-step program (30 sec at 95°C,
30 sec at 60°C, and 45 sec at 72°C). The PCR product
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light.
PKC activity assay
The activity of PKC in BV-2 cells following LPS treat-
ment was measured using a PKC activity assay kit from
Assay Designs, Inc (Ann Arbor, MI). In brief, BV-2 cells
cultured in 24-well plates were treated with 1 μg/ml
LPS for 30 min and then washed with cold PBS twice
and lysed with protein lysis buffer. Whole cell lysates
were adjusted to equal protein concentrations with lysis
buffer and the same volume of each sample was added
to ELISA plates pre-coated with crebtide, a substrate
that can be readily phosphorylated by PKC. ATP was
added to each well to initiate reaction at 30°C for 90
min. After emptying the contents of each well, phos-
phospecific substrate antibody was added and incubated
for 1 hr. The phosphorylated crebtide was quantitated
following the manufacturer’s instructions.
Western blot analysis
Whole cell lysates from cultured BV-2 cells were
obtained by using ice-cold protein lysis buffer (contain-
ing 1 × TBS, 1% Nonidet P-40, 0.5% sodium deoxycho-
late, 0.1% SDS, 0.004% sodium azide) with freshly added
protease inhibitor cocktail and glycerophosphate and
sodium orthovanadate. The lysates were subjected to
centrifugation at 10,000 g for 10 min at 4°C. 5 μgo f
whole cell lysates were boiled for 5 min, and separated
on Novex 4-12% Bis-Tris gel. Proteins were transferred
to PVDF membrane using a Bio-Rad mini-trans-blot
cell. Transferred blots were blocked by incubating the
membranes with 5% BSA for 1 hr at room temperature
to reduce non-specific binding. Blocked membranes
were incubated with primary antibodies overnight.
These antibodies include rabbit polyclonal anti-phos-
phorylated and total ERK1/2, JNK and p38 (all with
dilution of 1:1000), mouse anti-iNOS (1:1000), mouse
anti-PKC a, b, δ, ε and g (BD Transduction Labora-
tories, 1:1000) and rabbit anti-PKC h, l, θ and ζ
polyclonal antibodies (Santa Cruz, all with 1:500 dilu-
tion). After washing with 1 × TBS-T (Tris-buffered sal-
ine containing 1% Tween 20), the membranes were
incubated with goat anti-rabbit or goat anti-mouse
horseradish peroxidase (HRP) conjugated secondary
antibody (1:2000) for 1 hr at room temperature. Finally,
the membranes were incubated in Chemiluminescence
western blot detection reagents from Pierce (Rockford,
IL) for 1 min and protein was visualized with Image
Reader LAS-3000 software.
Nitrite measurement
The level of accumulated nitrite in the medium was
determined by the Greiss reaction. Briefly, 50 μlo f
Greiss reagent (3.9 mM N-(1-naphthyl)ethylenediamine/
58 mM sulfanilamide/5% phosphoric acid) was added to
50 μl of culture supernatant in a 96-well plate. Absor-
bance was measured at wavelength 550 nm, and nitrite
concentration was calculated from a standard curve of
sodium nitrite.
siRNA transfection
In order to specify the role of each PKC isoform in
iNOS induction by LPS-activated microglia, double-
stranded siRNA oligonucleotides for each PKC isoform
(purchased from Santa Cruz) were transfected into BV-2
cells with X-treme transfection reagent (60 nmol
siRNA/well). The day before the transfection, BV-2 cells
were split and plated into 24-well plates at a density of
2×1 0
5 cells/well to assure cells around 80% confluency
at the time of transfection. The transfected cells were
continuously incubated at 37°C for 48 hr before use for
further experiments. siGLO RISC-free siRNA from
Dharmacon was used as a negative control and its fluor-
escence was also used for evaluating transfection
efficiency.
Plasmid transfection and luciferase assay
The reporter gene with NF-B promoter was transfected
into BV-2 cells. In brief, the cells were trypsinized and
Table 1 Primer sequences of mouse PKC isoforms.
PKC isoform Forward Reverse
a 5’- cccattccagaaggagatga - 3 ’ 5’- ttcctgtcagcaagcatcac - 3 ’
b 5’- tccctgatcccaaaagtgag - 3 ’ 5’- aacttgaaccagccatccac - 3 ’
δ 5’- cagaccaaggaccacctgtt - 3 ’ 5’- gcataaaacgtagcccggta - 3 ’
g 5’- accagggcatcatctacagg - 3 ’ 5’- cttcctcatcttccccatca - 3 ’
ε 5’- gaggactggattgacctgga - 3 ’ 5’- atctctgcagtgggagcagt - 3 ’
h 5’- catcccacacaagttcaacg - 3 ’ 5’- atatttccgggttggagacc - 3 ’
l 5’-t a t g g c t t c a g c g t t g a c t g-3’ 5’- cctttgggtccttgttgaga - 3 ’
θ 5’- atggacaaccccttctaccc - 3 ’ 5’- gcggatgtctcctctcactc - 3 ’
ζ 5’- aagtgggtggacagtgaagg - 3 ’ 5’- cagcttcctccatcttctgg - 3 ’
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4 cells/
well. The transfection was performed with FuGene HD
transfection reagent. One microgram plasmid containing
NF-B promoter or GFP was mixed with 0.25 μl
FuGene HD in a total volume of 5 μlo fs e r u m - f r e e
DMEM for each reaction. At 24 hr after transfection,
cells were treated with LPS for 3 hr in the presence of
various PKC and MAPK inhibitors. Assessment of luci-
ferase activity in transfected cells was carried out with a
luciferase reporter assay system from Promega following
the manufacturer’s instructions.
Statistical analysis
Data were analyzed for statistical significance using a
two-tailed t test (comparison of two data sets) or with
analysis of variance (ANOVA, comparison of multiple
data sets). A significant difference was determined as p
< 0.05. All experiments were performed in triplicate and
have been repeated at least three times.
Results
ALL PKC isoforms are present in microglia and activated
by LPS
It has been reported that inhibitors of PKC can reduce
iNOS induction in reactive microglia [28-30]. However,
the specific PKC isoforms that are involved are not
known. In order to identify the specific PKC isoforms
that are required for iNOS production, we first exam-
ined which PKC isoforms are expressed in BV-2 by
quantitative real-time PCR.T h er e s u l t si n d i c a t et h a t
while mRNAs encoding all the PKC isoforms are detect-
able, there are significantly higher levels of nPKC (δ, h,
ε) expression compared to the conventional (a, b, g)
and the atypical (l/ι) isoforms (Figure 1A). Using iso-
form-specific antibodies, we found that each of the PKC
isoforms is also expressed in BV-2 cells (Figure 1B). In
contrast to a report by Kang and colleagues [31], but
consistent with results from Sun’sg r o u p[ 2 9 ] ,w e
detected very low amounts of PKC a and b and very
high levels of PKC δ, suggesting that nPKC isoforms
may account for the major PKC activity in reactive
microglia. In order to confirm PKC is activated in LPS-
treated microglia, we measured PKC activity in murine
BV-2 cells using ELISA. As shown in Figure 1C, PKC
activity is elevated after treatment with LPS for 30 min,
and suppressed by several PKC inhibitors, which include
the pan-PKC inhibitor, Bis-1, the nPKC-selective inhibi-
tor, rottlerin, and the cPKC-selective inhibitor, GO6976
[32,33]. These results demonstrate that both cPKC and
nPKC might be functionally important in BV-2 cells
when activated by LPS.
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Figure 1 Expression and activation of various PKC isoforms in
BV-2 cells. A, RNA samples isolated from the BV-2 cells were
analyzed by quantitative real-time PCR, using primer pairs (see
table 1) specific for mouse PKC a, b, g, δ, ε, θ, h, ζ and l.G A P D H
was used as an internal control. A representative experiment of
three that were performed is shown. B, Twenty micrograms of
whole cell lysate from BV-2 cells for the detection of each PKC
isoform was subjected to western blots with antibodies against
PKC a, b, g, δ, ε, θ, h, ζ and l. A representative experiment of
three that were performed is shown. C, BV-2 cells were treated
with LPS (1 μg/ml) in the absence or presence of PKC inhibitors
for 30 min and then lysed for assaying the PKC activity. CON, RO,
GO and BIS stand for control, rottlerin, GO6976 and
bisindolylmaleimide-1, respectively. All the PKC inhibitors
completely blocked LPS-induced increases in PKC activity in BV-2
cells. **, p < 0.01 were obtained when the LPS alone-treated
group was compared to the control and the drug-treated groups.
A representative experiment of three that were performed is
shown.
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microglia
The discovery of relatively isozyme-specific PKC inhibi-
tors has provided important information regarding the
function of individual PKC isoforms. It has been
reported that rottlerin specifically inhibits PKC δ while
GO6976 mainly targets conventional PKC, and Bis-1 has
inhibitory effects on all PKC isozymes [32,33]. To deter-
mine whether iNOS induction is attributable to the acti-
vation of PKC, BV-2 cells were treated with LPS in the
presence of the aforementioned PKC inhibitors. At 6 hr
following LPS treatment, cells were lysed and iNOS pro-
duction was determined by western blot. All of the PKC
inhibitors were able to suppress iNOS expression to dif-
ferent degrees. However, rottlerin seems to have the
greatest inhibitory effect (Figure 2A). In comparing
these, rottlerin at 5 μM near completely (94%) blocks
LPS-induced iNOS production, GO6976 at 5 μMc a u s e s
60% inhibition and Bis-1 at 10 μM inhibits iNOS pro-
duction by 89% (Figure 2B). Consistently, NO produc-
tion was also significantly attenuated when cells were
treated with PKC inhibitors (Figure 2C). These results
confirm that PKC activation is an integral component of
LPS-induced iNOS expression and suggest that nPKC
isoforms might play a prominent role in iNOS induction
in BV-2 cells.
Activation of MAPK occurs downstream PKC, but
upstream iNOS induction in reactive microglia
It is well known that MAPK cascades are involved in
cytokine- and LPS-mediated iNOS induction in micro-
glial cells [34]. However, the involvement of specific
MAPKs varies in different cell types and in response to
different stimuli. At various times after LPS treatment,
all three MAPKs in BV-2 cells are transiently phos-
phorylated. p38 phosphorylation occurs at 5 min,
reaches maximum at 30 min, and nearly disappears at 1
hr following LPS treatment. The phosphorylation of
JNK and ERK1/2 is present after 15 min of LPS treat-
ment and remains at the same level until 30 min, fol-
lowed by a dramatic reduction at 1 hr (Figure 3).
Using U0126, SB203580 and SP600125, inhibitors of
E R K 1 / 2 ,p 3 8a n dJ N K ,r e s p e c t i v e l y[ 3 5 ] ,w ef o u n dt h a t
iNOS induction and NO production in reactive micro-
glia were significantly inhibited (Figure 4A-C). There
was no change in cell viability at 24 hr following drug
treatment (data not shown). To investigate the possible
relationship between PKCs and MAPKs, we examined
activation of MAPKs in the presence of PKC inhibitors.
We found that MAPK phosphorylation at 15 min fol-
lowing LPS treatment is attenuated by PKC inhibitors,
indicating that activation of PKC occurs upstream of
MAPKs. The nPKC selective inhibitor rottlerin attenu-
ates ERK1/2 phosphorylation by 63%, but has no effect
A
R
O
 
3
ȝ
M
ȕ-actin
iNOS
C
O
N
LPS
R
O
 
5
ȝ
M
G
O
 
5
ȝ
M
B
I
S
 
1
0
ȝ
M
C
O
N
B
*** ***
**
***
C
r
e
l
a
t
i
v
e
 
i
n
t
e
n
s
i
t
y
N
i
t
r
i
t
e
 
c
o
n
c
e
n
t
r
a
i
o
n
(
%
 
o
f
 
c
o
n
t
r
o
l
)
LPS
**
*** ***
Figure 2 Effects of PKC inhibitors on iNOS expression in BV-2
cells. A, BV-2 cells were treated with LPS (1 μg/ml) for 6 hr in the
presence of PKC inhibitors at the indicated concentrations. Aliquots
of cell extracts prepared from the above treated cultures were
subjected to western blot analysis by using antibodies against iNOS
and b-actin. A representative experiment of four that were
performed is shown. B, The levels of iNOS expression with various
treatment conditions were normalized by b-actin and quantified
using densitometric analysis. The data were pooled from 4 different
experiments. **, p < 0.01 and ***, p < 0.001 were obtained when
the GO, RO and BIS treated groups were compared to the LPS
alone group. C. At 24 hr following LPS (1 μg/ml) treatment in the
absence or presence of PKC inhibitors, culture media from 24-well
plates were collected for measurement of nitrite production by
reactive microglia. **, p < 0.01 and ***, p < 0.001 were obtained
when the GO-, RO- and BIS-treated groups were compared to the
LPS alone group. A representative experiment of four that were
performed is shown.
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GO6976, a cPKC selective inhibitor, not only attenuates
the phosphorylation of ERK1/2 by 83%, but also sup-
presses the phosphorylation of p38 and JNK by 60% and
47%, respectively (Figure 4D). The general PKC inhibi-
tor, Bis-1, inhibits phosphorylation of ERK1/2 by 40%
and JNK by 30%. Taken together, these results suggest
that although all of the MAPKs are involved in induc-
tion of iNOS in LPS-treated microglia, activation of spe-
cific PKC isoforms may lead to phosphorylation of
distinct MAPKs.
Activation of NF-B contributes to PKC-mediated iNOS
induction in reactive microglia
NF-B is one of the primary transcription factors that
regulates iNOS expression. The regulation of iNOS
mediated by ERK1/2 and p38 MAPK has been shown to
require NF-B activation in rat glial cells [34,36]. In this
study, we also investigated whether NF-B is involved in
PKC-mediated iNOS production. CAY10470 is a
recently developed NF-B inhibitor. It is synthesized
from quinazoline derivative 6a, containing 4-phenoxy-
phenethyl moiety at the C(4)-position with an IC50 of 11
nM to inhibit NF-B activation in human Jurkat cells
[37]. CAY10470 significantly reduces iNOS production
(Figure 5A), implying the involvement of NF-Ba c t i v a -
tion in iNOS production induced by LPS in BV-2 cells.
To further examine the interaction of PKC activation
and NF-B during LPS treatment, we transfected BV-2
cells with an NF-B-responsive luciferase construct con-
taining an NF-B response element and luciferase. This
construct encodes the firefly luciferase reporter gene
under the control of a minimal CMV promoter and tan-
dem repeats of the NF-B transcriptional response ele-
ment (TRE). The NF-B reporter (Luc) can easily and
rapidly monitor NF-B activity in the cells. Our data
demonstrate that luciferase activity induced by LPS is
significantly inhibited in the presence of the PKC inhibi-
tors, rottlerin, GO6976 and Bis-1 (Figure 5B). Similarly,
U0126 and SB203580 also significantly repress NF-B
activity (Figure 5B). Taken together, these results indi-
cate that NF-B acts downstream of PKC and MAPKs
to transcriptionally regulate iNOS production.
The differential role of PKC isoforms in LPS-induced iNOS
production and MAPK activation in BV-2 cells
The above results suggest that LPS-induced iNOS pro-
duction is mediated by PKC activation and MAPK phos-
phorylation. However, because of the lack of specificity
and the potential non-target effects of the pharmacologi-
cal inhibitors, it is still unclear whether specific PKC
isoforms mediate microglial activation by LPS. To test
this, we employed RNAi technologies to transfect BV-2
cells with isoform-specific siRNAs to suppress the
expression of various PKC isoforms. To test for trans-
fection efficiency, we used siGLO RISC-free siRNA as a
positive control. siGLO RISC-free siRNA is a stable,
fluorescent, and non-targeting control siRNA with
RISC-free modification. Following 48 hr of transfection,
at least 90% of cells were transfected (Figure 6A). The
transfection efficiency was further demonstrated by
downregulation of various PKC isoforms (PKCa, b, θ, δ,
ε and h) using PKC isoform-specific siRNAs by both
conventional and quantitative real-time PCR analysis
(Figures 6B and 6C). qRT-PCR data indicated that speci-
fic PKC siRNA downregulates relative PKC isoform
mRNA level by 3-5 fold.
We then examined how downregulation of each speci-
fic PKC isoform could affect iNOS induction in BV-2
cells. At 48 hr following PKC siRNA transfection, cells
were treated with LPS for 6 hr and iNOS expression
was assessed by western blot (Figure 7A, B). Among the
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Figure 3 Time course of MAPK activation induced by LPS in
BV-2 cells. BV-2 cells were treated with LPS (1 μg/ml) for 5, 15, 30
min, 1 or 2 hr and whole cell lysates at different time points were
collected and subjected to western blot with antibodies against
phosphorylated and total p38, JNK and ERK1/2, respectively.
Phosphorylation of p38 occurred at 5 min following LPS treatment,
whereas phosphorylation of ERK1/2 and JNK was observed after 15
min of LPS treatment. The phosphorylation of all three MAPKs
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experiment of three that were performed is shown.
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Page 6 of 13nPKC isoforms, knockdown of PKC δ appears to have
the greatest inhibitory effect on iNOS expression, with a
more-than-3-fold reduction observed. PKC h and θ
knockdown reduces iNOS by almost 2-fold, and knock-
down of PKC ε shows little effect (Figure 7A). Interest-
ingly, downregulation of PKC b,b u tn o tP K Ca,
significantly attenuates iNOS induction (Figure 7B),
even though a very low mRNA expression of both cPKC
isoforms is observed in BV-2 cells (Figure 1A, B). There
is a 3-fold reduction in iNOS expression in PKC b
siRNA-transfected cells when compared to RISC-free
siRNA-transfected controls (Figure 7B). In summary,
these data demonstrate that each PKC isoform has a dif-
ferent potency in triggering iNOS induction in LPS-
activated microglia and that selective inhibition of PKC
δ or b may provide more focused anti-inflammatory
effects.
To further identify the specific MAPK pathway
through which PKC regulates the expression of iNOS,
we examined the effect of PKC siRNAs on phosphoryla-
tion of various MAPKs. Similar to the results obtained
using PKC inhibitors (Figure 4), downregulation of
nPKCs produces various degrees of inhibition of the
phosphorylation of ERK1/2 (Figure 8A). Knockdown of
PKC δ almost completely blocks ERK1/2 activation.
PKC h siRNA is shown to inhibit ERK1/2 phosphoryla-
tion by 60%, but PKC ε and θ siRNAs have no effect.
Interestingly, PKC θ siRNA causes a 75% reduction of
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Figure 4 Involvement of MAPK pathways in LPS-induced iNOS production in BV-2 cells. A-B, BV-2 cells were treated with LPS (1 μg/ml) for
6 hr in the presence of SB205380 (SB), SP600125 (SP) or U0126 (U); inhibitors to block phosphorylation of p38, JNK (A) and ERK1/2 (B),
respectively. The three MAPK inhibitors almost completely blocked iNOS induction in LPS-activated microglia. A representative experiment of
three that were performed is shown. C. BV-2 cells were treated with MAPK inhibitors followed by LPS induction for 24 hr. Culture media were
collected for measurements of nitrite production using a nitrite/nitrate assay kit. ***, p < 0.001 was obtained when the SB-, SP- and U-treated
groups were compared to the LPS alone group. A representative experiment of four that were performed is shown. D, BV-2 cells were treated
with LPS (1 μg/ml) for 15 min in the presence of PKC inhibitors at the indicated concentrations. Cell extracts from the treated cells were
subjected to western blot with antibodies against phosphorylated and total ERK1/2, p38 and JNK. The relative intensities of phosphorylated
versus total ERK1/2, p38 and JNK were quantified using densitometric analysis based on 3 different experiments. *, p < 0.05 and **, p < 0.01
were obtained when the drug-treated groups were compared to the LPS alone group.
Wen et al. Journal of Neuroinflammation 2011, 8:38
http://www.jneuroinflammation.com/content/8/1/38
Page 7 of 13phosphorylation of p38 in LPS-treated microglia (Figure
8A), even though rottlerin doesn’t exhibit any inhibitory
effect (Figure 4C). Compared to the results obtained by
using the cPKC inhibitor GO6976 (Figure 3C), we found
that PKC b,b u tn o tP K Ca siRNA, efficiently blocks
phosphorylation of p38 by 65% based on densitometric
analysis of the relative intensity of western blot bands
(Figure 8B). However, both PKC a and b siRNAs display
nearly 50% inhibitory effects on ERK1/2 phosphorylation
(Figure 8B). In addition, the isoform-specific PKC
siRNAs do not affect phosphorylation of JNK (Figure
8A, B), suggesting JNK activation is not involved in
iNOS induction downstream of PKC activation. These
results not only suggest that various PKC isoforms con-
trol diverse downstream MAPKs pathways to affect
LPS-induced iNOS production in murine microglia, but
also further demonstrate that the commonly used PKC
inhibitors are less selective and that the use of individual
PKC siRNAs should be more suitable for elucidating sig-
naling pathways mediated by the various PKCs.
Discussion
Overproduction of NO by enhanced iNOS induction has
been tightly linked to neuroinflammatory and neurode-
generative diseases [38-40]. A better understanding of
the signaling mechanisms involved in the regulation of
microglial iNOS has potential therapeutic implications.
Previous studies mostly used PKC activators and inhibi-
tors to determine the role of PKC in the regulation of
iNOS production in murine microglia [26-30]. However,
the absence of selectivity and the potential off-target
effects of these pharmacological agents limit the ability
to further define isoform-specific functions of the var-
ious PKCs. In the present study, we have employed PKC
isoform-specific siRNAs to delineate novel molecular
signaling pathways linking PKC to iNOS induction in
BV-2 cells when exposed to LPS.
Role of the PKC specific isoforms in LPS-induced iNOS
production
The PKC family consists of at least 10 serine/threonine
protein kinases originally characterized by their depen-
dency on lipids for catalytic activity [41,42]. The
cPKCs require DAG and Ca
2+, the nPKCs require
DAG but not Ca
2+, while the aPKCs require neither.
The different modes of PKC regulation suggest that
PKC isoforms may function differently in response to
various stimuli. In BV-2 cells, pharmacological inhibi-
tion studies suggest that the nPKC and cPKC isoforms
are integral to LPS-induced increases in iNOS expres-
sion and NO production (Figure 2), and isoform-speci-
fic siRNA knockdown confirms that PKC δ and PKC b
are the major nPKC and cPKC isoforms involved in
the regulation of LPS-induced iNOS production in
murine microglia (Figure 7).
A number of studies have reported that particular
PKC isoforms are involved in the production of NO in
several different cell types [28,43-45]. Here we demon-
strate a principal role for PKC δ and PKC b in the
response to LPS exposure in murine BV-2 cells. These
results are not only consistent with previous studies
showing that PKC δ activation is required for regulating
the production of iNOS in mouse peritoneal macro-
phages [27], human leukemia cells [46] and BV-2 cells
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inhibitor. Cell lysates were subjected to western blot analysis with
antibodies against iNOS and b-actin. A representative experiment of
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shown.
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Page 8 of 13[29], but also for the first time suggest that PKC b
might play an important role in LPS-induced iNOS pro-
duction in BV-2 cells even with its low levels of expres-
sion. It might be concluded that the primary role of
PKC δ results from its high expression relative to other
PKC isoforms (Figures 1A and 1B). However, PKC b
expression is relatively low (Figure 1A) suggesting that
induction of iNOS is dependent not only on levels of
expression, but also on the activation of distinct PKC
isoforms. Interestingly, PKC a and ε have been shown
to be the major PKC isoforms involved in the signaling
pathways by which IFNg induces iNOS expression in
the same cell line [28]. Collectively, these results suggest
that distinct PKC isoforms are activated and implicated
in the regulation of iNOS induction in a stimulus-speci-
fic manner.
Downstream components of PKC activation in LPS-
induced iNOS expression
MAPKs. In the present study we also explored signaling
pathways downstream of PKC that increase iNOS
expression in response to LPS exposure. In general
agreement with the observed effects of the three PKC
inhibitors, rottlerin, GO6976, and Bis-1 (Figure 4D),
knockdown of PKC δ, h, a and b expression reduces
LPS-induced phosphorylation of ERK1/2 (Figures 8A
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Figure 6 Downregulation of PKC isoforms by specific PKC siRNA. A, BV-2 cells transfected with DY-547 labeled RISC-free siRNA in 24-well
plate were photographed using a Nikon Eclipse TE2000-U. The white field shows total cells, TRITC represents positively transfected cells, and
merge stands for overlaid images. B, BV-2 cells were transfected with individual PKC isoform-specific siRNAs for 48 hr. Total RNAs were isolated
from each transfected group for analysis of gene expression by reverse transcriptase PCR using primer pairs specific for PKC δ, ε, θ, h, a, b and
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was used as a loading control. C, Total mRNA was extracted from BV-2 cells that were transfected with PKC isoform siRNA or RISC free control
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SYBR Green PCR Master mix. ***, p < 0.001 were obtained when the PKC siRNA transfected groups were compared to the RISC-free siRNA
control group. A representative experiment of three that were performed is shown.
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Page 9 of 13and 8B), whereas downregulation of PKC b significantly
inhibits LPS-induced phosphorylation of p38 (Figure
8B). No effect on phosphorylation of JNK is observed
with individual cPKC or nPKC siRNA (Figures 8A and
8B). Taken together, these results provide strong evi-
dence that ERK1/2 and p38 are the main signaling path-
ways through which distinct PKC isoforms regulate
iNOS induction in response to LPS. Moreover, these
results suggest that distinct MAPKs are activated by
specific PKC isoforms.
It has been shown that both p38 and ERK1/2 can
mediate iNOS expression in glial cells [36]. However,
the phosphorylation of ERK1/2 has been found to be
involved in IFNg-, but not in LPS-induced NO
production, although NO production seems to be
coupled to PKC δ activation under both stimulations
[29]. The discrepancy between this report and our cur-
rent study is unclear, but may be attributable to differ-
ences in the stage of BV-2 cells used in these studies.
The same group has recently found that paraquat toxi-
city to microglia is mediated by PKC δ-a n dE R K 1 / 2 -
dependent ROS generation [47]. The fact that neither
nPKCs nor cPKCs affect JNK phosphorylation (Figure 6)
suggests that JNK is not involved in the signaling path-
way of iNOS induction coupling to PKC activation.
Interestingly, PKC θ siRNA significantly blocks p38
phosphorylation (Figure 8A), although the commonly
used nPKC inhibitor rottlerin has no inhibitory effect
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Page 10 of 13(Figure 4D). Similarly, GO6976 blocks JNK activation
(Figure 4D) but the same phenomenon is not observed
with the use of cPKC siRNAs (Figure 8B). These results
further suggest that it might be misleading to draw con-
c l u s i o n so nt h er o l eo fs p e c i f i cP K Ci s o f o r m si nt h e
function of reactive microglia on the basis of pharmaco-
logical inhibition.
NF-B. It is known that iNOS expression is transcrip-
tionally regulated. Activation of p38 has been shown to
regulate NF-B, C/EBP, and ATF-2 to induce iNOS
expression in rat astroglia [48]. However, HIV-1 Tat-
induced iNOS expression in human astrocytes is depen-
dent on phosphorylation of ERK1/2 and transcriptional
activation of C/EBP, but not NF-B [49]. These studies
indicate that different transcription factors can be
recruited via one or more kinase pathways with respect
to different inducers of iNOS. In this study, we find that
activation of NF-B is required for iNOS induction
through the application of CAY10470, an NF-B-specific
inhibitor (Figure 5). The observation that all of the PKC
inhibitors - GO6976, rottlerin and Bis-1 - significantly
block NF-B activation strongly supports the conclusion
that NF-B activation is required for iNOS induction in
LPS-treated BV-2 cells.
Conclusions
By using pharmacological inhibitors and RNA interfer-
ence, we have clearly demonstrated that LPS-induced
iNOS expression and NO production in BV-2 is
mediated by a signaling pathway involving the sequential
activation of PKC, MAPK and NF-B as illustrated in
Figure 9. In addition to elucidating the critical role of
PKC δ in ERK1/2 phosphorylation and iNOS induction,
our study reveals that PKC b is also a principal PKC iso-
form triggering iNOS induction in reactive microglia,
which is coupled through phosphorylation of p38. The
partial inhibitory effects of PKC h and θ on iNOS
induction are due to their attenuation of the phosphory-
lation of ERK1/2 and p38, respectively. These data sug-
gest that a novel interaction between the distinct PKC
isoforms and the various MAPKs promotes iNOS induc-
tion. This interaction in different cell types may help to
explain the discrepancy in the literature, and may also
help guide the design of novel and selective PKC
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Page 11 of 13inhibitors for the treatment of many inflammatory and
neurological diseases in which overproduction of nitric
oxide plays a pathogenic role.
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